Announced
Completed
Financials
Tags
genetic medicines
Majority
Friendly
Pharmaceuticals
Domestic
drug discovery
United States
Acquisition
Public
Single Bidder
Completed
Synopsis
Eli Lilly and Company, a distributor of pharmaceutical products, completed the acquisition of Akouos, a genetic medicine company, for $610m. "I am proud of the commitment and passion of our team, which has established Akouos as a pioneer in inner ear genetic medicine, as demonstrated by our work to advance the first investigational therapy for a genetic form of hearing loss into clinical development. Joining Lilly – a company that shares our purpose to make life better for people around the world – will help us accelerate the development of a broad pipeline of inner ear genetic medicines," Emmanuel Simons, Akouos Co-Founder, President and CEO.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.